Study: 29% of infants protected against RSV after nirsevimab, maternal vaccination - NAPNAP

Study: 29% of infants protected against RSV after nirsevimab, maternal vaccination

Study: 29% of infants protected against RSV after nirsevimab, maternal vaccination

By /
Powered by Americaneagle.com

Website design and development by Americaneagle.com, Inc.